Primary Immune Deficiency Clinical Trials

3 recruiting

Primary Immune Deficiency Trials at a Glance

9 actively recruiting trials for primary immune deficiency are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Baltimore, Milwaukee, and San Francisco. Lead sponsors running primary immune deficiency studies include New York Medical College, Icahn School of Medicine at Mount Sinai, and Imagine Institute.

Browse primary immune deficiency trials by phase

Treatments under study

About Primary Immune Deficiency Clinical Trials

Looking for clinical trials for Primary Immune Deficiency? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Primary Immune Deficiency trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Primary Immune Deficiency clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

Primary Immune Deficiency
National Institute of Allergy and Infectious Diseases (NIAID)5,000 enrolled7 locationsNCT00246857
Recruiting
Phase 1Phase 2

Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

Viral InfectionPrimary Immune Deficiency Disorder
New York Medical College40 enrolled7 locationsNCT04197596
Recruiting

Biologics And Clinical Immunology Cohort at Sinai

Autoimmune DiseasesImmunological DiseasePrimary Immune Deficiency
Icahn School of Medicine at Mount Sinai800 enrolled1 locationNCT04784364
Recruiting
Phase 2

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

Dyskeratosis CongenitaFanconi AnemiaBone Marrow Failure+7 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins27 enrolled1 locationNCT04232085
Recruiting
Phase 2

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Epstein-Barr Virus InfectionsPrimary Immune Deficiency Disorder
New York Medical College20 enrolled8 locationsNCT03266653
Recruiting
Phase 2

Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

AdenovirusPrimary Immune Deficiency Disorder
New York Medical College20 enrolled10 locationsNCT03266627
Recruiting
Phase 2

Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

Cytomegalovirus InfectionsPrimary Immune Deficiency Disorder
New York Medical College20 enrolled9 locationsNCT03266640
Recruiting
Phase 2

TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Metabolic DiseasePrimary Immune Deficiency Disorders
Johns Hopkins All Children's Hospital17 enrolled1 locationNCT04414046
Recruiting

COVID-19 in PID Survey

COVIDPrimary Immune Deficiency
Imagine Institute200 enrolled1 locationNCT04459689